Antibiotics Market Size Worth $62.5 billion by 2026 - KBV Research

The Cell Wall Synthesis Inhibitors market dominated the Global Antibiotics Market by Action Mechanism in 2019, growing at a CAGR of 3.8 % during the forecast period. The Protein Synthesis Inhibitors market is expected to witness a CAGR of 4.3% during (2020 - 2026).

The Cephalosporin market dominated the Global Antibiotics Market by Drug Class in 2019. The Penicillin market is estimated to grow at a CAGR of 3.6% during (2020 - 2026). The Fluoroquinolone market would exhibit a CAGR of 6.4% during (2020 - 2026).

The Asia Pacific market dominated the Global Antibiotics Market by Region in 2019, due to the larger population, increasing cases of infectious disease, and lenient regulation on antibiotics drugs. It is also expected that it will continue to maintain its dominance during the forecast period. This is due to the increasing consumption of antibiotics, their easy availability, and the increasing sales of over-the-counter drugs. The Europe market is exhibiting a CAGR of 4.9% during (2020 - 2026). Additionally, The North America market would showcase a CAGR of 3.9% during (2020 - 2026).

Full Report: https://www.kbvresearch.com/antibiotics-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.

Global Antibiotics Market Segmentation

By Action Mechanism

• Cell Wall Synthesis Inhibitors


• Protein Synthesis Inhibitors


• DNA Synthesis Inhibitors


• RNA Synthesis Inhibitors,


• Mycolic Acid Inhibitors

By Drug Class

• Cephalosporin


• Penicillin


• Fluoroquinolone


• Macrolides


• Carbapenem


• Aminoglycosides


• Sulfonamides,


• Others

By Geography

North America

• US


• Canada


• Mexico


• Rest of North America

Europe

• Germany


• UK


• France


• Russia


• Spain


• Italy


• Rest of Europe

Asia Pacific

• China


• Japan


• India


• South Korea


• Singapore


• Malaysia


• Rest of Asia Pacific

LAMEA

• Brazil


• Argentina


• UAE


• Saudi Arabia


• South Africa


• Nigeria


• Rest of LAMEA

Companies Profiled

• GlaxoSmithKline PLC (GSK)


• Johnson and Johnson


• Merck & Co., Inc.


• Pfizer, Inc.


• Bayer AG


• Novartis AG


• Sanofi S.A.


• Abbott Laboratories


• Hoffmann-La Roche Ltd.


• Eli Lilly and Company